Medizen Humancare Inc Co., Ltd.
KKRX:2363401,300.00
KRW
-99.00
(-7.08%)
Medizen Humancare Inc Co., Ltd.
KRX:236340
(Korea Stock Exchange)
Recent
price
1,300.00
P/E
ratio
15.78
div
yld
- -
ROIC.AI
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.- Similar Companies
- Business
- Medizen Humancare Inc. is a South Korea-based biotechnology and precision healthcare company primarily engaged in the development and commercialization of personalized genomic analysis, molecular diagnostics, and predictive disease risk profiling solutions. Founded in 2012 and headquartered in Seoul, South Korea, the company operates in the digital healthcare and genetic diagnostics industry, serving medical institutions, health examination centers, corporate enterprises, and individual consumers across domestic and international markets. The company offers a comprehensive suite of diagnostic and health analytics services, which includes: M-CHECK, a proprietary personalized genetic analysis service that assesses hereditary predisposition and risk factors for major cancers, cardiovascular conditions, metabolic disorders, and chronic adult diseases; MELTHY, an integrated digital healthcare and precision wellness platform delivering tailored nutrition, dietary supplement, and lifestyle recommendations based on multi-omics data; Direct-to-Consumer (DTC) personal genetic testing kits evaluating fitness, weight management, skincare, hair loss, and nutrient metabolism markers; clinical molecular diagnostic test kits and reagents for pathogen detection and biomarker screening; human gut and skin microbiome sequencing services; and artificial intelligence-powered multi-omics data analytics for predictive and preventive medicine. Medizen Humancare distributes its products and services domestically through partnerships with hospitals, specialized health screening centers, life insurance companies, and digital commerce channels. Internationally, the company conducts business and distribution operations across key global markets, including Vietnam, the Philippines, Indonesia, China, and the Middle East, leveraging localized diagnostic partnerships and joint venture testing facilities. In recent operations, Medizen Humancare has expanded its international footprint by establishing strategic joint ventures and regional laboratory partnerships across Southeast Asia to deploy localized genomic screening services. The company has broadened its commercial DTC genetic testing portfolio in response to expanded regulatory frameworks and updated its MELTHY platform with AI-driven algorithm enhancements for personalized functional food integration. Additionally, Medizen Humancare has formed collaborative alliances with insurance carriers, telecommunications firms, and wellness product manufacturers to supply bundled precision health tracking subscriptions, while advancing development on multi-omics biomarker panels for clinical diagnostics.